Actinium Announces Announced Five Abstracts Accepted For Presentation At 2024 SNMMI Annual Meeting
Actinium Announces Announced Five Abstracts Accepted For Presentation At 2024 SNMMI Annual Meeting
Actinium 宣佈宣佈五份摘要獲准在 2024 年 SNMMI 年會上發表
- Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of the patient journey
-Iomab-B 和 Actimab-A 是唯一針對急性髓系白血病的靶向放射療法，可針對患者旅程的不同部分
- Improved survival demonstrated with both Iomab-B and Actimab-A in patients with high-risk acute myeloid leukemia including those with a TP53 mutation and prior venetoclax treatment
-Iomab-B 和 Actimab-A 均顯示高風險急性髓系白血病患者（包括 TP53 突變且之前接受過 venetoclax 治療的患者）的存活率有所提高
- Novel linker technology supports Actinium's Antibody Radiation Conjugate pipeline expansion in solid tumor indications
-新的連接器技術支持實體瘤適應症中Actinium的抗體輻射偶聯物管線擴展
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。